fda warning letters compounded semaglutide telehealth 2024 2025 Last month, the issued 25 to companies over what it called false or misleading claims about GLP-1 medications. Read more at the link in the comments below FDA ramps up its pushback

Safety and tolerability The safety and tolerability profile of retatrutide was generally consistent with other incretin-based therapies such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro)

GLP-1 research quickly opened the door to an entirely new class of metabolic compounds

Not because the process is complicated, but because small errors in technique degrade the peptide before you ever draw your first dose

We stripped away the guesswork and replaced it with strict in-house protocols and verified data

No compound-specific stability data exists for compounded retatrutide vials, so applying the same care is the practical default

You can also calculate your waist-to-hip ratio